Background Pembrolizumab and atezolizumab have recently been approved for the first-line
treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for …

Background Combinations of immune checkpoint inhibitors (ICI) with platinum-based
chemotherapy (PlatinumCT) or with another ICI in the first-line setting for patients with …

Abstract Purpose of Review Advanced urothelial carcinoma (aUC) has long been treated
preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible …

Abstract Purpose of Review Until recently, effective treatment options for patients with
advanced urothelial carcinoma were limited to platinum-based chemotherapy. In the post …

Background Few options exist for patients with locally advanced or metastatic urothelial
carcinoma after progression with platinum-based chemotherapy. We aimed to assess the …

Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have
led to US Food and Drug Administration (FDA) approval of five novel anti-programmed cell …

Background Limited data compare first-line carboplatin-based chemotherapy and immune
checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients …

Aims: Immune checkpoint inhibitors (ICIs) have recently revolutionized the treatment
landscape of metastatic urothelial carcinoma. The authors performed a meta-analysis …

Combination platinum-based chemotherapy has been the standard of care for several
decades in first-line treatment of advanced urothelial carcinoma (UC) patients. UC is often …